Author(s): Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, et al.
Importance:Current hypothetical models emphasize the importance of β-amyloid in Alzheimer disease (AD) pathogenesis, although amyloid alone is not sufficient to account for the dementia syndrome. The impact of small-vessel cerebrovascular disease, visualized as white matter hyperintensities (WMHs) on magnetic resonance imaging scans, may be a key factor that contributes independently to AD presentation.
Objective:To determine the impact of WMHs and Pittsburgh Compound B (PIB) positron-emission tomography-derived amyloid positivity on the clinical expression of AD.
Design:Baseline PIB-positron-emission tomography values were downloaded from the Alzheimer's Disease Neuroimaging Initiative database. Total WMH volume was derived on accompanying structural magnetic resonance imaging data. We examined whether PIB positivity and total WMHs predicted diagnostic classification of patients with AD (n = 20) and control subjects (n = 21). A second analysis determined whether WMHs discriminated between those with and without the clinical diagnosis of AD among those who were classified as PIB positive (n = 28). A third analysis examined whether WMHs, in addition to PIB status, could be used to predict future risk for AD among subjects with mild cognitive impairment (n = 59).
Participants:The study involved data from 21 normal control subjects, 59 subjects with mild cognitive impairment, and 20 participants with clinically defined AD from the Alzheimer Disease's Neuroimaging Initiative database.
Main outcome measures:Clinical AD diagnosis and WMH volume.
Results:Pittsburgh Compound B positivity and increased total WMH volume independently predicted AD diagnosis. Among PIB-positive subjects, those diagnosed as having AD had greater WMH volume than normal control subjects. Among subjects with mild cognitive impairment, both WMH and PIB status at baseline conferred risk for future diagnosis of AD.
Conclusions and relevance:White matter hyperintensities contribute to the presentation of AD and, in the context of significant amyloid deposition, may provide a second hit necessary for the clinical manifestation of the disease. As risk factors for the development of WMHs are modifiable, these findings suggest intervention and prevention strategies for the clinical syndrome of AD.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/23420027
Author(s): Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, et al.
Author(s): Guerchet M, Aboyans V, Nubukpo P, Lacroix P, Clément JP, et al.
Author(s): Hanon O, Haulon S, Lenoir H, Seux ML, Rigaud AS, et al.
Author(s): Hilal S, Saini M, Tan CS, Catindig JA, Dong YH, et al.
Author(s): Price JF, McDowell S, Whiteman MC, Deary IJ, Stewart MC, et al.
Author(s): Sugawara N, Yasui-Furukori N, Umeda T, Kaneda A, Sato Y, et al.
Author(s): Caruana MF, Bradbury AW, Adam DJ.
Author(s): Drouet L
Author(s): Henry-Feugeas MC
Author(s): Brandts A, van Elderen SG, Westenberg JJ, van der Grond J, van Buchem MA, et al.
Author(s): Hughes TM, Kuller LH, Barinas-Mitchell EJ, Mackey RH, McDade EM, et al.
Author(s): King KS, Chen KX, Hulsey KM, McColl RW, Weiner MF, et al.
Author(s): Kuo HK, Chen CY, Liu HM, Yen CJ, Chang KJ, et al.
Author(s): Rosano C, Watson N, Chang Y, Newman AB, Aizenstein HJ, et al.
Author(s): Saji N, Kimura K, Shimizu H, Kita Y
Author(s): Saji N, Shimizu H, Kawarai T, Tadano M, Kita Y, et al.
Author(s): Tsao CW, Seshadri S, Beiser AS, Westwood AJ, Decarli C, et al.
Author(s): Bots ML, van Swieten JC, Breteler MM, de Jong PT, van Gijn J, et al.
Author(s): Debette S, Markus HS
Author(s): Ovbiagele B, Saver JL
Author(s): Pantoni L, Garcia JH
Author(s): Au R, Massaro JM, Wolf PA, Young ME, Beiser A, et al.
Author(s): Henskens LH, Kroon AA, van Oostenbrugge RJ, Gronenschild EH, Fuss-Lejeune MM, et al.
Author(s): Mitchell GF
Author(s): Iadecola C, Park L, Capone C
Author(s): de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, et al.